Fig. 2
From: Immune characteristics and clinical significance of peripheral blood lymphocytes in breast cancer
Features of PBL subsets before treatment. (A). Box plots of the distribution of baseline PBL subsets in all BC patients; blue text indicates below the reference value. (B-C). Baseline PBL subset characteristics of patients receiving (B) adjuvant therapy and (C) NAT. (D). Relationship between baseline PBL subsets and treatment regimen, Mann–Whitney U test. (E-G). The proportion of baseline PBL subsets in various molecular subtypes in (E) all patients and (F) patients receiving adjuvant therapy, (G) NAT. *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: NAT, neoadjuvant therapy; HR + HER2-, hormone receptor-positive/HER2-negative; HER2+, HER2-positive; TN, triple-negative